Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc is experiencing a positive outlook due to the significant clinical success of its therapeutic candidate, zanidatamab, which has shown highly statistically significant improvements in both progression-free survival and overall survival in recent trials. The company is well-positioned to generate robust revenue through a tiered royalty structure linked to peak sales estimates exceeding $1 billion for its lead candidate, Ziihera, while also having a deep preclinical pipeline that enhances its long-term growth potential. Financially, Zymeworks operates from a position of strength with $299 million in cash and an additional $440 million linked to near-term milestones, providing substantial resources to support ongoing and future development initiatives.

Bears say

Zymeworks Inc. faces significant risks that could negatively impact its stock price, particularly if its key clinical candidate, zanidatamab, fails to demonstrate sufficient efficacy or safety in ongoing trials, potentially leading to halted development and diminished investor confidence. Additional concerns include the company's challenges with scaling manufacturing processes for biparatopic antibodies, obtaining necessary regulatory approvals, and the risk of competitive pressures affecting the commercial potential of its therapeutic pipeline. Furthermore, the need for capital in a volatile market raises the specter of potential insolvency and shareholder dilution, which could further weigh on the company's valuation.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.